Supreme Court Reverses Patent Ruling 9-0 in Generic Drug Case, Clarifying Skinny-Label Standard
Updated
Updated · Newsweek · Jun 4
Supreme Court Reverses Patent Ruling 9-0 in Generic Drug Case, Clarifying Skinny-Label Standard
3 articles · Updated · Newsweek · Jun 4
Summary
A 9-0 Supreme Court ruling sent Hikma Pharmaceuticals USA v. Amarin Pharma back to lower courts after overturning an appeals decision that had allowed Amarin’s patent-infringement claims to proceed.
Justice Ketanji Brown Jackson’s opinion clarified when generic drugmakers can face liability for inducing infringement even if they use “skinny labels” that omit patented uses from their marketing.
That standard matters because generic manufacturers said a win for Amarin could have chilled lower-cost competition, while the case also affects how companies describe drug uses and risks.
The dispute centers on Amarin’s Vascepa and Hikma’s proposed generic version, filed under the Hatch-Waxman framework that governs competition between brand-name and generic medicines.
The unanimous decision also stands out on a court often framed as ideologically split and adds to Jackson’s small but notable set of 9-0 opinions this term.
Did the Supreme Court's ruling make it harder for drug companies to develop new, life-saving uses for existing medicines?
With this new protection for generic drugs, how quickly could Americans see lower prices at the pharmacy counter?
Supreme Court’s 9-0 Ruling in Hikma v. Amarin Secures Skinny Label Pathway, Paving Way for Cheaper Generics and Drug Savings
Overview
On June 4, 2026, the Supreme Court unanimously ruled in favor of generic drugmaker Hikma in the case against Amarin, reversing the Federal Circuit’s earlier decision. This landmark ruling is a major win for the generic drug industry, as it clarifies the legal standard for induced patent infringement under the 'skinny label' pathway. Justice Jackson explained that inducement requires clear, purposeful actions, not just ordinary product distribution. By declining to create a new pharmaceutical-specific standard, the Court provided much-needed clarity and stability, ensuring that generic competition can continue and patients have better access to affordable medications.